Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.

Abstract

PURPOSE Our aim is to investigate the usefulness of metric indices in post-marketing safety evaluations by estimating number needed to harm (NNH) values for cardiovascular (CV) adverse outcomes for rosiglitazone and pioglitazone. METHODS Reports from regulatory authorities (RAs) were consulted, and Medline searches were performed to identify studies… (More)
DOI: 10.1002/pds.3874

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics